These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 10585700)

  • 1. Millennium mergers bring pipeline.
    Dove A
    Nat Biotechnol; 1999 Dec; 17(12):1151. PubMed ID: 10585700
    [No Abstract]   [Full Text] [Related]  

  • 2. What does R&D really cost?
    Huff B
    GMHC Treat Issues; 2001; 15(7-8):1-7. PubMed ID: 11548507
    [No Abstract]   [Full Text] [Related]  

  • 3. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development.
    Lee VH
    Drug Discov Today; 2005 Nov; 10(21):1411-4. PubMed ID: 16243258
    [No Abstract]   [Full Text] [Related]  

  • 4. Investing in risk management.
    Fiscus PW
    Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaceutical manufacturers ... leaving tradition behind and forging new managed care alliances.
    Barnett AA
    State Health Care Am; 1995; ():41-6. PubMed ID: 10168072
    [No Abstract]   [Full Text] [Related]  

  • 6. Bring the magic back to the bullets.
    Nat Biotechnol; 2006 Dec; 24(12):1489. PubMed ID: 17160046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trials and error.
    Jacobs T
    Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
    [No Abstract]   [Full Text] [Related]  

  • 8. BIO and biogenerics.
    Feldbaum CB
    Nat Biotechnol; 2005 Jan; 23(1):17; discussion 17. PubMed ID: 15637607
    [No Abstract]   [Full Text] [Related]  

  • 9. Biogenerics standoff.
    Herrera S
    Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
    [No Abstract]   [Full Text] [Related]  

  • 10. King of the pill. Pfizer is the biggest drug company ever. Can it become the best?
    Simons J
    Fortune; 2003 Apr; 147(7):94-6, 100, 102. PubMed ID: 12698860
    [No Abstract]   [Full Text] [Related]  

  • 11. Spinning the wheel on ImClone.
    Varchaver N
    Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
    [No Abstract]   [Full Text] [Related]  

  • 12. Nutraceuticals: poised for a healthy slice of the healthcare market?
    Brower V
    Nat Biotechnol; 1998 Aug; 16(8):728-31. PubMed ID: 9702769
    [No Abstract]   [Full Text] [Related]  

  • 13. A critical tipping point.
    Zuckerman MB
    US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366
    [No Abstract]   [Full Text] [Related]  

  • 14. Biotech industry struggles with generics approval.
    Knight J
    Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190316
    [No Abstract]   [Full Text] [Related]  

  • 15. Concerns raised over declining antiinfectives R&D.
    Fox JL
    Nat Biotechnol; 2003 Nov; 21(11):1255-6. PubMed ID: 14595340
    [No Abstract]   [Full Text] [Related]  

  • 16. HHS: POUFA reauthorization good for Americans.
    FDA Consum; 2002; 36(5):5. PubMed ID: 12412536
    [No Abstract]   [Full Text] [Related]  

  • 17. Can China bring its own pipeline to the market?
    Louët S
    Nat Biotechnol; 2004 Dec; 22(12):1497-9. PubMed ID: 15583646
    [No Abstract]   [Full Text] [Related]  

  • 18. This Dutchman is flying.
    Watson N
    Fortune; 2003 Jun; 147(13):89-90. PubMed ID: 12827720
    [No Abstract]   [Full Text] [Related]  

  • 19. Biotech's next big blowup?
    Stires D
    Fortune; 2002 Mar; 145(6):154. PubMed ID: 11913033
    [No Abstract]   [Full Text] [Related]  

  • 20. Marketplace. How drug company mergers affect HMOs and hospitals.
    Moskowitz DB
    Faulkner Grays Med Health; 1997 Jun; 51(23):suppl 2 p.. PubMed ID: 10167794
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.